Current trends in nonoperative management for rectal adenocarcinoma: An unequal playing field?. Issue 8 (3rd September 2022)

• Record Type: Journal Article
• Authors: Lee, Katherine C.; Zhao, Beiqun; Pianka, Kurt; Liu, Shanglei; Eisenstein, Samuel; Ramamoorthy, Sonia; Lopez, Nicole E.
• Is Part Of: Journal of surgical oncology. Volume 126:Issue 8(2022)
• Page Start: 1504
• Page End: 1511
• Publication Date: 2022-09-03
• Subjects: colorectal cancer -- guideline concordant care -- healthcare disparities -- nonoperative management -- rectal cancer; Cancer -- Surgery -- Periodicals; Neoplasms -- Periodicals; 616
• DOI: 10.1002/jso.27082
• Languages: English
• ISSNs: 0022-4790

Abstract

Abstract: Background and Objectives: Increasing evidence suggests patient‐oriented benefits of nonoperative management (NOM) for rectal cancer. However, vigilant surveillance requires excellent access to care. We sought to examine patient, socioeconomic, and facility‐level factors associated with NOM over time. Methods: Using the National Cancer Database (2006–2017), we examined patients with Stage II–III rectal adenocarcinoma, who received neoadjuvant chemoradiation and received NOM versus surgery. Factors associated with NOM were assessed using multivariable logistic regression with backward stepwise selection. Results: There were 59, 196 surgical and 8520 NOM patients identified. NOM use increased from 12.9% to 15.9% between 2006 and 2017. Patients who were Black (adjusted odds ratio [aOR]: 1.36, 95% confidence interval [CI]: 1.26–1.47), treated at community cancer centers (aOR: 1.22, 95% CI: 1.12–1.30), without insurance (aOR: 1.87, 95% CI: 1.68–2.09), and with less education (aOR: 1.53, 95% CI: 1.42–1.65) exhibited higher odds of NOM. Patients treated at high‐volume centers (aOR: 0.79, 95% CI: 0.74–0.84) and those who traveled >25.6 miles for care (aOR: 0.59, 95% CI: 0.55–0.64) had lower odds of NOM. Conclusions: Vulnerable groups who traditionally have difficulty accessing comprehensive cancer care were more likely to receive NOM, suggesting that healthcare disparities may be driving utilization. More research is needed to understand NOM decision‐making in rectal cancer treatment.